Abstract
A variety of oxazolones (3-18) with structural variation at C-2 and C-4 were synthesized and evaluated as chymotrypsin inhibitors. The synthesized compounds showed varying degree of chymotrypsin inhibitory activity ranging IC50 values from 12.62 ± 1.32 - 126.57 ± 1.06 μM, if compared to standard chymostatin (IC50 = 7.01 ± 0.1 μM). Compounds 3,9,10,13,14, and 15 have IC50 values 17.03 ± 0.78, 69.05 ± 1.48, 12.62 ± 1.32, 17.29 ± 0.93, 126.57 ± 1.06, and 31.55 ± 1.31 μM, respectively. This study reveals that the substitution of functional group (s) at C-2 and C-4 positions plays a vital role in the activity of this series of compounds. The size and electron donating or withdrawing effects of substituents influenced the activity.
Keywords: Synthesis, Oxazolone Derivatives, Chymotrysin inhibition
Letters in Drug Design & Discovery
Title: Synthesis and Chymotrypsin Inhibitory Activity of Substituted Oxazolones
Volume: 5 Issue: 1
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Muhammad Arif Lodhi and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Synthesis, Oxazolone Derivatives, Chymotrysin inhibition
Abstract: A variety of oxazolones (3-18) with structural variation at C-2 and C-4 were synthesized and evaluated as chymotrypsin inhibitors. The synthesized compounds showed varying degree of chymotrypsin inhibitory activity ranging IC50 values from 12.62 ± 1.32 - 126.57 ± 1.06 μM, if compared to standard chymostatin (IC50 = 7.01 ± 0.1 μM). Compounds 3,9,10,13,14, and 15 have IC50 values 17.03 ± 0.78, 69.05 ± 1.48, 12.62 ± 1.32, 17.29 ± 0.93, 126.57 ± 1.06, and 31.55 ± 1.31 μM, respectively. This study reveals that the substitution of functional group (s) at C-2 and C-4 positions plays a vital role in the activity of this series of compounds. The size and electron donating or withdrawing effects of substituents influenced the activity.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Mughal Rasool Uzma, Lodhi Arif Muhammad and Choudhary Iqbal Muhammad, Synthesis and Chymotrypsin Inhibitory Activity of Substituted Oxazolones, Letters in Drug Design & Discovery 2008; 5 (1) . https://dx.doi.org/10.2174/157018008783406624
DOI https://dx.doi.org/10.2174/157018008783406624 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Life and Death of Leukemic Cells Under Bcr-Abl Signaling Control
Current Cancer Therapy Reviews Green Synthesized Nanomaterials as Theranostic Platforms for Cancer Treatment: Principles, Challenges and the Road Ahead
Current Medicinal Chemistry Targeting Cancer Cells by an Oxidant-Based Therapy
Current Molecular Pharmacology Concise Synthesis of Benzoindolizidine Derivatives and Bioactivity Evaluation
Letters in Organic Chemistry An Update on Extemporaneous Preparation of Radiopharmaceuticals Using Freeze-Dried Cold Kits
Mini-Reviews in Medicinal Chemistry Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform
Current Pharmaceutical Design Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Current Radiopharmaceuticals Alpha-1-Antitrypsin Deficiency and Mechanisms of Liver Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Design Graph Theoretical Analysis and In Silico Modeling of Dunaliella Bardawil Biomass Encapsulated N-Succinyl Chitosan Nanoparticles for Enhanced Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Characterizing the Latent HIV-1 Reservoir in Patients with Viremia Suppressed on cART: Progress, Challenges, and Opportunities
Current HIV Research Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets The “Tilted Peptide Theory” Links Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides
Protein & Peptide Letters Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials